BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell
February 07 2022 - 7:45AM
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”)
(NASDAQ: BRTX), a clinical-stage company focused on stem cell-based
therapies, today announced that Lance Alstodt, BioRestorative’s
Chairman and CEO, along with Francisco Silva, Vice President of
Research and Development, have been invited to ring the closing
bell at Nasdaq’s stock market closing on Monday, February 7th at
4:00 PM ET in celebration of BioRestoriative’s uplisting to Nasdaq.
The ceremony will begin at approximately 3:45PM ET and can be
viewed live at
https://livestream.com/accounts/27896496/events/9988418 .
"We are honored to ring the closing bell in
celebration of our recent uplisting. Our goal is to validate our
technology through the regulatory process positioning the Company
as a leader in the global cellular therapy market," commented Mr.
Alstodt.
"Over the past decade, we have built a strong
foundation of science, clinical translation and intellectual
property and we look forward to expanding our pipeline into the
clinic and developing therapeutics to help those with unmet medical
needs,” said Mr.Silva.
Mr. Alstodt added, "We would like to thank all
of our employees for their hard work and the incredible milestones
we have achieved to date. We are very excited to take the next step
in our growth story as we continue to enhance BioRestorative’s
profile and execute on our strategic plan as a publicly-traded
company on Nasdaq."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process utilizes
proprietary technology and involves collecting a patient’s bone
marrow, isolating and culturing stem cells from the bone marrow and
cryopreserving the cells. In an outpatient procedure, BRTX-100 is
to be injected by a physician into the patient’s damaged disc. The
treatment is intended for patients whose pain has not been
alleviated by non-invasive procedures and who potentially face the
prospect of surgery. We have received authorization from the Food
and Drug Administration to commence a Phase 2 clinical trial using
BRTX-100 to treat chronic lower back pain arising from degenerative
disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024